Filing Flows

Filing Flows › Companies › Pacira BioSciences › Cash flow

Pacira BioSciences cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$46.4M in Q3 2026 · $169M over twelve months

Operating cash flow$50.1M
Capital spending−$3.6M
Free cash flow+$46.4M
Cash / net income1.8×
Cash conversion cycle349 days

Analysis

In Q3 2026, Pacira BioSciences generated $50.1M of operating cash flow and spent $3.6M on capital projects, leaving free cash flow of $46.4M. That is $10.5M less than in Q3 2025 ($57.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was $177M; the largest uses were buybacks ($98.3M), net borrowing (+) / repaid (−) ($85.0M), taxes on employees’ shares ($8.1M); besides operations, cash came from other investing ($126M), other financing ($1.6M); the cash balance rose by $99.4M.

Operating cash flow was $50.1M against net income of $28.5M — 1.8× profit, cash ran ahead of reported earnings. The largest differences: depreciation & amortization +$19.3M, stock-based pay +$11.8M, prepaid and other assets −$10.8M.

Its cash conversion cycle was 349 days (receivables 66 + inventory 326 − payables 43).

Free cash flow

Pacira BioSciences: free cash flow by quarterPacira BioSciences: free cash flow by quarter$31.0MQ4 2024$26.9MQ1 2025$9.3MQ2 2025$57.0MQ3 2025$43.5MQ4 2025$23.0MQ1 2026$56.1MQ2 2026$46.4MQ3 2026
Operating cash flow less capital spending.
Pacira BioSciences: operating cash flow against capital spendingPacira BioSciences: operating cash flow against capital spendingOperating cash flowCapital spending$33.1M$2.1MQ4 2024$35.5M$8.5MQ1 2025$12.0M$2.7MQ2 2025$60.8M$3.9MQ3 2025$43.7M$218KQ4 2025$25.7M$2.7MQ1 2026$57.5M$1.3MQ2 2026$50.1M$3.6MQ3 2026
Latest (Q3 2026): Operating cash flow $50.1M, Capital spending $3.6M.

Capital allocation, year by year

Pacira BioSciences: where the cash came from (up) and went (down), by fiscal yearPacira BioSciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $126MFY2021: Net borrowing $364MFY2021: Shares issued $23.8MFY2021: Capital spending −$45.9MFY2021: Acquisitions −$420M$513MFY2021FY2022: Operating cash flow $145MFY2022: Net borrowing −$78.1MFY2022: Shares issued $24.4MFY2022: Capital spending −$30.1M$170MFY2022FY2023: Operating cash flow $155MFY2023: Net borrowing $150MFY2023: Shares issued $1.9MFY2023: Capital spending −$15.2M$306MFY2023FY2024: Operating cash flow $189MFY2024: Capital spending −$10.6MFY2024: Buybacks −$25.0M$189MFY2024FY2025: Operating cash flow $152MFY2025: Net borrowing $91.0MFY2025: Shares issued $502KFY2025: Capital spending −$15.3MFY2025: Acquisitions −$16.7MFY2025: Buybacks −$148M$243MFY2025
Over these 5 years operating cash flow totalled $767M; the largest uses were acquisitions ($437M) and buybacks ($173M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$296M
Debt$294M
Net cash$2.0M

Pacira BioSciences funds itself: free cash flow was $169M over the last twelve months, and $296M of cash and investments stands against $294M of debt.

Where the cash came from and went

Pacira BioSciences: sources (+) and uses (−) of cash, Q3 2026Pacira BioSciences: sources (+) and uses (−) of cash, Q3 2026Other investing$70.4MNet borrowing (+) / repaid (−)−$70.0MOperating cash flow$50.1MCash drawn (+) / kept (−)−$41.1MAcquisitions−$6.0MCapital spending−$3.6MShares issued$375KTaxes on employees’ shares−$145KExchange rates−$30K
Pacira BioSciences: sources (+) and uses (−) of cash, TTM to Q3 2026Pacira BioSciences: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$177MOther investing$126MCash drawn (+) / kept (−)−$99.4MBuybacks−$98.3MNet borrowing (+) / repaid (−)−$85.0MTaxes on employees’ shares−$8.1MCapital spending−$7.9MAcquisitions−$6.3MOther financing$1.6MShares issued$1.3MExchange rates−$406K

From profit to cash

Pacira BioSciences: net income to operating cash flow, Q3 2026Pacira BioSciences: net income to operating cash flow, Q3 2026Net income$28.5MDepreciation & amortization$19.3MStock-based pay$11.8MDeferred taxes−$714KReceivables$9.7MInventory$4.9MPayables−$1.6MAccrued liabilities$10.4MPrepaid and other assets−$10.8MOther liabilities−$845KOperating cash flow$50.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20266632643349
Q2 20266129432322
Q1 20266337536402
Q4 20255635437373
Q3 20255941064405
Q2 20255531459310
Q1 20255834055342
Q4 20245327344282

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$50.1M−$3.6M−$6.0M—−$70.0M$375K−$41.1M$46.4M
Q2 2026$57.5M−$1.3M——−$5.0M$457K−$61.6M$56.1M
Q1 2026$25.7M−$2.7M−$335K−$50.0M−$5.0M$2K$14.2M$23.0M
Q4 2025$43.7M−$218K—−$48.2M−$5.0M$490K−$11.0M$43.5M
Q3 2025$60.8M−$3.9M—−$50.0M−$104M$12K$153M$57.0M
Q2 2025$12.0M−$2.7M—−$50.0M−$3.8M—−$16.9M$9.3M
Q1 2025$35.5M−$8.5M−$16.7M—−$2.8M—−$6.8M$26.9M
Q4 2024$33.1M−$2.1M————−$30.8M$31.0M

Pacira BioSciences: income statement and cash flow

Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%. The chart follows the revenue to costs, profit and cash.

Pacira BioSciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.